AB Science SA is primarily active in the pharmaceutical industry.

The main competitors of AB Science SA in the market are other pharmaceutical companies operating in the same therapeutic areas. These include major players such as Novartis, Pfizer, and Roche. AB Science SA faces competition in the development and commercialization of its products, particularly in the fields of oncology and rare diseases. The company strives to differentiate itself through its innovative pipeline and unique research approach. However, it operates in a highly competitive landscape where technological advancements and regulatory challenges play a significant role in shaping market dynamics.

AB Science SA is a renowned biopharmaceutical company founded in 2001. Headquartered in France, AB Science is dedicated to developing innovative therapies for life-threatening diseases with unmet medical needs. The company focuses on developing small molecules targeting tyrosine kinase receptors. AB Science has a robust pipeline with a particular focus on oncology, inflammatory diseases, and neurodegenerative disorders. With a strong commitment to research and development, AB Science strives to improve patient outcomes through its cutting-edge therapeutic solutions. As a leading player in the biopharmaceutical industry, AB Science SA continues to make significant contributions to the advancement of medical science.

AB Science SA has achieved significant milestones in its journey. The company has successfully conducted extensive clinical trials, gaining regulatory approvals for its innovative therapies. AB Science SA has also secured strategic partnerships and collaborations with renowned institutes and organizations, enhancing its research and development capabilities. The company's commitment to scientific excellence has led to breakthrough discoveries and advancements in the field. With its continuous efforts and dedication, AB Science SA has emerged as a leader in the industry, delivering novel solutions and improving patient outcomes.

AB Science SA is primarily present in various countries and regions around the world. Some of the key areas where AB Science SA operates include France, the United States, and several European countries. With its headquarters located in Paris, France, AB Science SA has established a significant presence in the pharmaceutical industry globally. The company's dedication to innovative research and development in the field of targeted therapies has contributed to its global footprint, expanding its reach and influence in multiple markets to address various unmet medical needs.

AB Science SA represents values of innovation, commitment, and scientific rigor. As a biopharmaceutical company, AB Science SA focuses on developing cutting-edge therapies to address unmet medical needs. With a strong corporate philosophy that values patient-centricity and scientific excellence, AB Science SA is dedicated to advancing the understanding and treatment of severe diseases. Their commitment to research and development, alongside a patient-focused approach, drives their mission to improve the lives of patients worldwide. Through their groundbreaking discoveries and relentless pursuit of scientific advancements, AB Science SA is at the forefront of delivering innovative therapeutic solutions.

Analysts currently set an average price target of 3,79 EUR for the AB Science stock (median: 3,53 EUR), implying +463,0 % versus the latest price. The consensus is based on 9 analyst ratings.

AB Science Analītiķu cenu mērķi 2026

9 analysts currently rate the AB Science stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect AB Science to generate revenue of 1,13 M EUR and earnings per share of -0,15 EUR.

AB Science Analītiķu cenu mērķi 2026

The AB Science share (AB.PA) is listed on 8 stock exchanges, including: Frankfurt (A8D.F), München (A8D.MU), Düsseldorf (A8D.DU), London (0Q77.L), London (0Q77.L), Paris (AB.PA).

The French company AB Science SA is a biopharmaceutical company specializing in the development and marketing of innovative therapies for rare diseases and serious neurological conditions. The company's business model is based on creating and implementing a comprehensive and integrated portfolio of drug candidates for various diseases. AB Science combines internal research and development activities with strategic partnerships with leading academic institutions and companies in the healthcare field. AB Science's product range includes various drug candidates for rare and serious neurological diseases such as stomach cancer, amyotrophic lateral sclerosis (ALS), mastocytosis (a rare disease causing an excessive number of mast cells in the body), and Alzheimer's disease. One of the company's most promising products is Masitinib, an oral selective tyrosine kinase inhibitor currently undergoing phase 3 clinical trials for various indications. AB Science's business model consists of multiple divisions, each specializing in the development and marketing of drugs for specific diseases. The first division focuses on developing therapies for stomach cancer, with AB Science already having developed a highly effective treatment for this disease. The company plans to bring this medication to market soon. Another division of AB Science focuses on developing drugs for ALS, with the company currently testing a promising drug candidate called Masitinib in phase 3 clinical trials. The goal is to obtain approval for Masitinib as soon as possible and make it available to millions of ALS patients worldwide. Another important division of AB Science focuses on developing drugs for mastocytosis, with the company already having developed a highly effective treatment for this disease. The company plans to bring this medication to market soon. In addition to drug development, AB Science also collaborates closely with other companies and academic institutions to identify and develop new compounds and technologies. With its extensive experience in researching rare diseases and its innovative research and development of therapies, the company will remain a key player in the biopharmaceutical industry in the future. Overall, AB Science's business model is focused on creating and implementing a robust portfolio of drug candidates for rare and serious neurological diseases. The company relies on a combination of research and development, strategic partnerships, and experienced management to develop and market therapies for patients worldwide. With its diverse product portfolio and commitment to improving patients' quality of life, AB Science will continue to be a leading company in the biopharmaceutical industry.

gaidāmā apgrozījums AB Science ir 1,13 M EUR. Šis skaitlis ir balstīts uz pašreizējiem finanšu datiem un atspoguļo uzņēmuma biznesa sniegumu.

gaidāmā peļņa AB Science ir -8,18 M EUR. Neto peļņa atspoguļo uzņēmuma rentabilitāti pēc visu izdevumu atskaitīšanas.

AB Science cenas un peļņas rādītājs (P/E) pašlaik ir -3,52. P/E rādītājs salīdzina pašreizējo akcijas cenu ar peļņu uz akciju un palīdz ieguldītājiem novērtēt AB Science akcijas vērtību.

AB Science cenas un apgrozījuma rādītājs (P/S) pašlaik ir 25,44. P/S rādītājs salīdzina tirgus kapitalizāciju ar gada apgrozījumu un kalpo kā AB Science akcijas vērtības mērs.

AB Science Eulerpool kvalitātes rādītājs ir 2/10.

AB Science ISIN ir FR0010557264. ISIN (International Securities Identification Number) ir pasaulē unikāls vērtspapīru identifikators.

AB Science WKN ir A1CXBG. WKN (Wertpapierkennnummer) ir sešciparu vācu vērtspapīru identifikācijas numurs.

AB Science tikeris ir AB.PA. Tikeris tiek izmantots AB Science akciju tirdzniecībai biržā.

AB Science pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

AB Science tiek piešķirts nozarei "Veselība".

AB Science dividendes tiek izmaksātas EUR.